Core Insights - Eli Lilly's drugs, Anjoulai and Anjoulai Li (generic name: Mirikizumab), have been approved by the National Medical Products Administration for the treatment of moderate to severe active Crohn's Disease (CD) and Ulcerative Colitis (UC) in adults [1][3] Group 1: Product Approval and Significance - The approval of Anjoulai and Anjoulai Li marks a significant step for Eli Lilly in the inflammatory bowel disease (IBD) treatment field in China, being the first innovative drug approved in this area [1][3] - Anjoulai and Anjoulai Li are IgG4 monoclonal antibodies specifically targeting the IL-23 p19 subunit, selectively inhibiting the IL-23 pathway to modulate immune inflammatory responses [1][3] Group 2: Clinical Data and Efficacy - For Crohn's Disease, the VIVID-1 global phase 3 clinical study showed that 45% of patients in the Anjoulai group achieved clinical response at week 12 and clinical remission at week 52, compared to 20% in the placebo group (p<0.0001) [3] - In the same study, 38% of patients in the Anjoulai group achieved endoscopic response at week 52, compared to 9% in the placebo group (p<0.0001) [3] - For Ulcerative Colitis, the LUCENT global phase 3 clinical study indicated that 64% of patients in the Anjoulai group achieved clinical response after 12 weeks, with 24% achieving clinical remission, significantly outperforming the placebo group [4] Group 3: Safety Profile - In the VIVID-1 study, the most common adverse events reported in the Anjoulai group included COVID-19 infection, anemia, joint pain, headache, and upper respiratory infections [5] - The incidence of serious adverse events in the Anjoulai group was 2.8% after 12 weeks, compared to 5.3% in the placebo group, and serious infection rates were 0.7% versus 0.6% [5] - The discontinuation rate due to adverse events was lower in the Anjoulai group compared to the placebo group during both the induction and maintenance phases [5]

Core Viewpoint - Yuan Dong Biotech (688513.SH) has announced that its wholly-owned subsidiary Chengdu Youluo Biotech Co., Ltd. has initiated a Phase I clinical trial for its self-developed monoclonal antibody EP-0210 injection, targeting inflammatory bowel disease, with the first subject having been dosed recently [1] Group 1: Product Development - EP-0210 is a humanized IgG1 monoclonal antibody targeting human tumor necrosis factor-like ligand 1A (TL1A), aimed at treating inflammatory bowel disease [1] - The mechanism of action involves high-affinity binding to TL1A, blocking the pro-inflammatory signaling pathways mediated by TL1A, thereby providing therapeutic effects for inflammatory bowel disease [1] Group 2: Clinical Research and Efficacy - Preclinical studies have demonstrated that EP-0210 has a clear mechanism of action and significant efficacy in various inflammatory bowel disease models, showing good safety and effectiveness [1] - EP-0210 exhibits superior target activity and in vivo efficacy compared to the foreign competitor RVT-3101, potentially offering safer and more effective options for patients with inflammatory bowel disease [1]

Core Insights - The implementation of the new national medical insurance drug list in 2025 has enabled the first medical insurance prescription for Risankizumab in Nanjing, significantly reducing the economic burden on Crohn's disease patients and improving their quality of life [1][3]. Group 1: Disease Overview - Crohn's disease, a major subtype of inflammatory bowel disease (IBD), is characterized by chronic recurrent inflammation of the digestive tract and is often referred to as "green cancer" due to its severe impact on patients' quality of life [3]. - The incidence of IBD in East Asia is accelerating, with the number of patients in China increasing at a rate of 5% to 10% annually [3]. Group 2: Treatment Advancements - Risankizumab has demonstrated significant therapeutic advantages in clinical studies and has been approved in over 40 countries, benefiting more than 40,000 patients with proven safety and efficacy [3]. - As the first interleukin-23 inhibitor approved for treating moderate to severe active Crohn's disease, Risankizumab offers a more precise treatment option for patients [3]. Group 3: Clinical Center Development - The Gastroenterology Department at Taikang Xianlin Gu Lou Hospital is recognized as a provincial clinical key specialty and has made significant advancements under the leadership of renowned expert Professor Zou Xiaoping [5]. - The newly established Small Intestine and Inflammatory Bowel Disease Diagnosis and Treatment Center focuses on key aspects of IBD management, integrating diagnostic and therapeutic approaches for comprehensive patient care [6].

Core Viewpoint - China Antibody-B (03681) has submitted an Investigational New Drug (IND) application for SM17 targeting inflammatory bowel disease (IBD) to the National Medical Products Administration (NMPA), which has been accepted [1] Group 1: Drug Development and Clinical Trials - The IND approval allows the use of data from completed or ongoing Phase 1 clinical trials in healthy volunteers to support the advancement of IBD indications to Phase 2 clinical development [1] - SM17 is currently undergoing a formulation conversion bridging clinical trial, expected to complete by the end of February next year, with plans to enter Phase 2 clinical trials for atopic dermatitis (AD) by mid-2026 [4] Group 2: Mechanism of Action - SM17 is a novel humanized IgG4-k monoclonal antibody that targets the IL-25 receptor to modulate type II inflammatory responses, blocking the signaling cascade induced by IL-25, which is associated with inflammatory bowel diseases [2] - The drug has dual potential benefits in Crohn's disease (CD) by regulating Th17-driven inflammation and exhibiting anti-fibrotic effects, which may help improve complications such as bowel strictures and fistulas [2] Group 3: Market Opportunity and Unmet Medical Needs - IBD, including CD and ulcerative colitis (UC), presents significant unmet medical needs, with existing therapies failing to meet the needs of 20% to 50% of patients due to primary non-response or secondary loss of response [3] - The global annual cost for managing IBD is estimated to exceed $34 billion, highlighting the substantial market opportunity for effective treatments [3] - The expansion of SM17's indications from AD to IBD represents a significant clinical and commercial opportunity to address unmet medical needs in this area [4]

Core Viewpoint - Abivax, a French biotechnology company, has seen its market capitalization surge from under $500 million at the beginning of the year to over $8 billion, driven by positive data from its experimental drug for chronic inflammatory bowel disease [1] Group 1: Drug Potential - Investors are focused on the potential of Abivax's obefazimod for ulcerative colitis patients, with results expected in Q2 2026, which could lead to regulatory submission [2] - The company plans to release mid-stage trial results for obefazimod in treating Crohn's disease later this year [2] - Obefazimod is designed to regulate inflammation through upregulating a microRNA called miR-124, offering a differentiated safety profile compared to existing treatments [5][6] Group 2: Market Opportunity - Wolfe Research analysts estimate obefazimod could achieve peak sales of approximately €6 billion ($7 billion) and capture a significant market share in treating ulcerative colitis and Crohn's disease [6] - The inflammatory bowel disease (IBD) market is projected to reach around $30 billion by 2030 [6] Group 3: Acquisition Interest - Abivax is viewed as a potential acquisition target, with Truist Securities highlighting its strategic appeal [7] - Goldman Sachs has included Abivax in its list of stocks favored by hedge funds [7] Group 4: Analyst Sentiment - Wall Street analysts have a consensus rating of "Buy" or "Strong Buy" for Abivax, with an average target price between $120 and $130 [11]

Summary of Johnson & Johnson (NYSE: JNJ) 2025 Conference Call Company Overview - **Company**: Johnson & Johnson (J&J) - **Date of Conference**: November 17, 2025 - **Key Speakers**: Candace Long (Worldwide VP Immunology Global Commercial Strategy), David Lee (Global Immunology Therapeutic Area Head) Key Points Icotrokinra Development - **Product Description**: Icotrokinra is the first targeted oral peptide selective to the IL-23 receptor, seen as a transformative therapy for psoriasis [3][4] - **Clinical Data**: Phase three studies show it provides complete skin clearance and favorable safety, positioning it as a first-line systemic therapy for moderate to severe psoriasis [3][4] - **Market Opportunity**: Approximately 5 million Americans with moderate to severe psoriasis or inflammatory bowel disease (IBD) are not currently using biologic therapies, indicating a significant market opportunity [6] - **Approval Timeline**: Submission for regulatory approval was made in July 2025, with a confident expectation for a 2026 launch [4][5] Competitive Positioning - **Head-to-Head Studies**: Ongoing studies against Stelara, a leading biologic therapy, are expected to demonstrate superior efficacy [10][11] - **Manufacturing Capability**: J&J has invested heavily in manufacturing capabilities to meet global demand for Icotrokinra, ensuring readiness for large-scale launches [12] Market Expansion - **Impact on Biologics**: The introduction of Icotrokinra is expected to elevate discussions between clinicians and patients, potentially increasing the overall utilization of biologics [13][15] - **Patient Insights**: A study indicated that over 90% of patients currently on injectable therapies would prefer to switch to an oral option with similar efficacy and safety [18] Future Indications - **Expansion Beyond Psoriasis**: Pivotal studies for Crohn's disease and ulcerative colitis are underway, with positive initial data from the ulcerative colitis studies [5][22] - **Adolescent Studies**: Ongoing studies include adolescent populations to ensure comprehensive data at launch [22] Tremfya Performance - **Current Growth**: Tremfya is experiencing growth in psoriasis and psoriatic arthritis indications, with a focus on inhibiting structural damage in psoriatic arthritis [28][29] - **Market Share**: Over 50% of new patient starts in the IL-23 class for ulcerative colitis are attributed to Tremfya, indicating strong market penetration [30] Imavi Launch - **Unique Positioning**: Imavi is the first FcRn therapy with broad applicability across multiple patient segments, showing promise in myasthenia gravis [45][46] - **Market Potential**: Expected to be a $5 billion asset, with early signs of strong interest from neurologists for first-line use [47] Strategic Acquisitions - **Focus on Atopic Dermatitis and Respiratory Diseases**: J&J has secured multiple assets to address unmet needs in atopic dermatitis and respiratory diseases, which are large and underserved markets [51][52] - **Innovative Mechanisms**: The company is exploring various mechanisms, including IL-31 and TSLP, to enhance treatment efficacy in these complex diseases [54][56] Conclusion - **Overall Strategy**: J&J is focused on advancing its immunology portfolio through innovative therapies, strategic acquisitions, and a commitment to addressing significant unmet medical needs across various indications [58][59]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [1][5]. Core Insights - The report highlights the clinical efficacy of new treatments for Inflammatory Bowel Disease (IBD), emphasizing the need for innovative therapies due to existing medications' limitations [2][11]. - There is a growing global value for domestic innovative drugs, with several companies achieving significant milestones in clinical data and partnerships [3][4]. - The report suggests continuous monitoring of companies involved in IBD research and those with high-quality innovation capabilities [2][3]. Summary by Sections Market Performance - The overall A-share market increased by 1.42%, with the pharmaceutical sector rising by 1.13%, indicating a weaker performance compared to the broader market [1]. - The TTM price-to-earnings ratio for the pharmaceutical sector stands at 34.41x, which is at the 72.02 percentile of the past five years [1]. IBD Clinical Data - IBD is characterized by chronic inflammation, with a significant unmet clinical need, as evidenced by the rising patient numbers globally [11]. - Innovative treatment options are emerging, including TYK2 small molecules and IL-23 antibodies, showing preliminary advantages in clinical trials [2][11]. Company Profit Forecasts and Ratings - Key companies such as Mindray Medical, WuXi AppTec, and others are rated as "Outperform," with projected net profits for 2024 ranging from 1.4 billion to 116.7 billion CNY [4]. - The report provides detailed profit forecasts and PE ratios for various companies, indicating a positive outlook for those with innovative capabilities [4][5]. Recommended Companies - Companies to watch in the IBD space include 3SBio, EdiGene, and Innovent Biologics, which are actively developing new therapies [2][3]. - The report also highlights companies with strong innovation potential, such as Kelun-Biotech and CanSino Biologics, suggesting they are well-positioned for future growth [3][4].

Core Viewpoint - The approval of Janssen's Guselkumab injection (Tenuat) for the treatment of moderate to severe active Crohn's disease and ulcerative colitis in adults marks a significant advancement in addressing the rising incidence of these inflammatory bowel diseases (IBD) in China [1][2]. Group 1: Disease Overview - The incidence of Crohn's disease (CD) and ulcerative colitis (UC) has been steadily increasing in China over the past few decades, with a trend of earlier onset age [1]. - Crohn's disease is a chronic inflammatory condition that can affect the entire digestive tract, with symptoms including abdominal pain, diarrhea, and weight loss, and currently has no cure [1]. - Ulcerative colitis leads to inflammation of the digestive tract and can cause significant damage to the colon's mucosa, with symptoms such as frequent diarrhea and rectal bleeding, primarily affecting younger patients aged 20 to 49 [1]. Group 2: Treatment Efficacy - Tenuat is the first and only fully human monoclonal antibody that selectively neutralizes interleukin-23, providing sustained deep remission in the treatment of Crohn's disease and ulcerative colitis [2]. - Clinical trials have shown that Guselkumab demonstrates superior efficacy compared to Ustekinumab in achieving multiple controlled endoscopic endpoints for Crohn's disease treatment [2]. - Research indicates that within one year, 45%-50% of ulcerative colitis patients achieved clinical remission, and 34%-35% attained endoscopic remission [2].

Table of Contents As filed with the Securities and Exchange Commission on September 29, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ABIVAX SA C T Corporation System 1015 15th Street N.W., Suite 1000 Washington, D.C. 20005 Phone: +1 202 572 3133 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Nathan Ajiashvili Alison Haggerty La ...